Chinook Therapeutics Presents BION-1301 Interim Phase 1/2 Data in Patients with IgA Nephropathy (IgAN) at the 58th ERA-EDTA Virtual Congress
June 08, 2021 08:15 ET
|
Chinook Therapeutics, Inc.
BION-1301 has been well-tolerated to date in patients with IgAN, with no serious adverse events (SAEs) or treatment discontinuations due to adverse eventsPharmacokinetics (PK) of BION-1301 observed in...
Chinook Therapeutics to Host Conference Call and Webcast Featuring BION-1301 Data Presented at the 58th ERA-EDTA Congress
May 25, 2021 16:05 ET
|
Chinook Therapeutics, Inc.
SEATTLE, May 25, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics to Present at the 2021 RBC Capital Markets Global Healthcare Conference
May 13, 2021 16:05 ET
|
Chinook Therapeutics, Inc.
SEATTLE, May 13, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
May 12, 2021 16:05 ET
|
Chinook Therapeutics, Inc.
SEATTLE, May 12, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 04, 2021 16:15 ET
|
Chinook Therapeutics, Inc.
SEATTLE, May 04, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Presents Data During the ISN World Congress of Nephrology 2021
April 15, 2021 08:15 ET
|
Chinook Therapeutics, Inc.
Poster presentation on BION-1301 including Gd-IgA1 biomarker data in healthy volunteers from Parts 1 and 2 of the ongoing phase 1b study of BION-1301 and data from the phase 1 IV to SC bioavailability...
Chinook Therapeutics to Present at Upcoming Investor Conferences
April 08, 2021 16:30 ET
|
Chinook Therapeutics, Inc.
SEATTLE, April 08, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
April 07, 2021 16:05 ET
|
Chinook Therapeutics, Inc.
SEATTLE, April 07, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of Atrasentan in Proteinuric Glomerular Diseases
April 07, 2021 08:15 ET
|
Chinook Therapeutics, Inc.
Data from Initial Patient Cohorts of Phase 2 AFFINITY Study Expected to be Reported in 2022 SEATTLE, April 07, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a...
Chinook Therapeutics Announces Update on Non-Renal Legacy Programs from Aduro Biotech Merger
April 05, 2021 08:15 ET
|
Chinook Therapeutics, Inc.
Van Herk Investments to Form and Invest in Sairopa, a New Company Focused on Research and Development of B-Select Monoclonal Antibody Platform Programs VANCOUVER, British Columbia and SEATTLE, April ...